# Nintedanib in Patients With Advanced Esophagogastric Cancer

> **NCT02234596** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 34 (actual)

## Conditions studied

- Esophagogastric Adenocarcinoma

## Interventions

- **DRUG:** Nintedanib

## Key facts

- **NCT ID:** NCT02234596
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-04
- **Primary completion:** 2020-04-22
- **Final completion:** 2020-04-22
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2021-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02234596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02234596, "Nintedanib in Patients With Advanced Esophagogastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02234596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*